Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Item 5.02. Other Events.
On July 2, 2018, the Board of Directors (the “Board”) of Novelion Therapeutics Inc. (the “Company”) appointed Mark Corrigan, M.D. as Executive Chair of the Board and disbanded the Executive Committee, effective immediately. Also, on July 2, 2018, the Board appointed Mr. Hackman, the Company’s chief operating officer (who is serving as its principal executive officer), as Interim Chief Executive Officer. As Interim Chief Executive Officer, Mr. Hackman will report to the Board and continue to lead the Company’s operations.
As Executive Chair, Dr. Corrigan will serve in a supervisory role to the Company’s management team and will continue to perform the traditional duties of Board Chair. He will not have the authority of an executive officer and will not be an employee of the Company. Dr. Corrigan’s compensation in connection with his appointment as Executive Chair has not been determined at this time. Biographical information for Dr. Corrigan and Mr. Hackman can be found beginning on pages 4 and 7, respectively, of the Company’s amendment no. 1 to its Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on April 30, 2018.
A copy of the press release announcing these matters is attached hereto as Exhibit 99.1.
Item 5.02. Financial Statements and Exhibits.
(d)Exhibits.
|
ExhibitNo. |
Description |
|
Press Release, dated July 3, 2018 |
NOVELION THERAPEUTICS INC. ExhibitEX-99.1 2 pressrelease-newchairman.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Novelion Therapeutics Appoints Mark Corrigan,…To view the full exhibit click here
About Novelion Therapeutics Inc. (NASDAQ:NVLN)
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
